Wary Of Coronavirus Hype And Haste, Themis Looks To Future As Part Of Merck & Co.
Shared Culture Helped Seal Acquisition
Themis’ CEO on how Merck’s commitment to infectious diseases impressed him, and why regulators may not approve suboptimal COVID-19 vaccines.
You may also be interested in...
The expectation of a big second quarter sales decline proved true, but the situation is improving. Meanwhile, Merck & Co. is advancing two vaccines and an antiviral against the novel coronavirus.
While Moderna and others frontrunners aim for a 2020 emergency use approval, Merck believes a more deliberate approach will pay off in the long term.
Merck Sharp & Dohme will begin manufacturing licensed doses of Ervebo in Germany and will continue to send investigational vaccine doses to Democratic Republic of Congo.